ECSP055939A - Inmunizacion activa para generar anticuerpos para beta-a soluble - Google Patents

Inmunizacion activa para generar anticuerpos para beta-a soluble

Info

Publication number
ECSP055939A
ECSP055939A EC2005005939A ECSP055939A ECSP055939A EC SP055939 A ECSP055939 A EC SP055939A EC 2005005939 A EC2005005939 A EC 2005005939A EC SP055939 A ECSP055939 A EC SP055939A EC SP055939 A ECSP055939 A EC SP055939A
Authority
EC
Ecuador
Prior art keywords
beta
soluble
fragments
antibodies
disease
Prior art date
Application number
EC2005005939A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Nicki Vasquez
Frederique Bard
Peter A Seubert
Original Assignee
Wyeth Corp
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Neuralab Ltd filed Critical Wyeth Corp
Publication of ECSP055939A publication Critical patent/ECSP055939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EC2005005939A 2003-02-01 2005-08-01 Inmunizacion activa para generar anticuerpos para beta-a soluble ECSP055939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44415003P 2003-02-01 2003-02-01

Publications (1)

Publication Number Publication Date
ECSP055939A true ECSP055939A (es) 2006-04-19

Family

ID=32850829

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005939A ECSP055939A (es) 2003-02-01 2005-08-01 Inmunizacion activa para generar anticuerpos para beta-a soluble

Country Status (20)

Country Link
US (3) US20060188512A1 (OSRAM)
EP (1) EP1594969B1 (OSRAM)
JP (1) JP2006516639A (OSRAM)
KR (1) KR20050118669A (OSRAM)
CN (1) CN1745175A (OSRAM)
AU (1) AU2004209981B2 (OSRAM)
BR (1) BRPI0407058A (OSRAM)
CA (1) CA2513722A1 (OSRAM)
CR (1) CR7922A (OSRAM)
EC (1) ECSP055939A (OSRAM)
ES (1) ES2545765T3 (OSRAM)
HR (1) HRP20050670A2 (OSRAM)
MX (1) MXPA05008156A (OSRAM)
NO (1) NO20053862L (OSRAM)
NZ (1) NZ567324A (OSRAM)
PL (1) PL378571A1 (OSRAM)
RU (1) RU2390350C2 (OSRAM)
UA (1) UA87453C2 (OSRAM)
WO (1) WO2004069182A2 (OSRAM)
ZA (1) ZA200505782B (OSRAM)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
JP2005181711A (ja) 2003-12-19 2005-07-07 Ricoh Co Ltd 画像形成装置及びプロセスカートリッジ
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CN101027391A (zh) * 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
WO2006066049A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006121656A2 (en) 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
EP1896504B1 (en) 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
WO2007062088A1 (en) * 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
ES2454253T3 (es) 2005-12-12 2014-04-10 Ac Immune S.A. Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
WO2008021295A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8077343B1 (en) 2007-01-03 2011-12-13 Marvell International Ltd. Determining end of print job in handheld image translation device
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
SG188136A1 (en) * 2007-09-13 2013-03-28 Delenex Therapeutics Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
ES2445590T3 (es) 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR20160099732A (ko) * 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
KR101755065B1 (ko) * 2013-07-03 2017-07-06 경희대학교 산학협력단 에클랄바사포닌 또는 그 유도체를 포함하는 인지기능 장애 또는 집중력 장애 질환 예방 또는 치료용 약학 조성물
DE102016005169B3 (de) * 2016-04-29 2017-07-13 Forschungszentrum Jülich GmbH Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787140A (en) * 1971-10-04 1974-01-22 A Gregory Power plant
US6096318A (en) * 1973-05-07 2000-08-01 The Ohio State University Antigenically modified HCG polypeptides
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5208036A (en) * 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5096706A (en) * 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4912206A (en) * 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
CA2085127C (en) * 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
DE69233774D1 (de) 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
NZ249704A (en) * 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US5736141A (en) 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
PT652758E (pt) * 1992-06-18 2000-04-28 Harvard College Vacinas de toxina da difteria
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
JP4116072B2 (ja) * 1992-08-27 2008-07-09 バイオクローンズ（プロプライエタリー）リミテッド 逆向き、鏡像体および逆向き鏡像体合成ペプチド類似物
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
CA2143848C (en) 1992-10-01 2007-09-11 W. Clark Still Complex combinatorial chemical libraries encoded with tags
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CA2115811A1 (en) * 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JPH08508252A (ja) * 1993-03-17 1996-09-03 アメリカ合衆国 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
ES2150493T5 (es) * 1993-05-25 2004-07-01 Wyeth Holdings Corporation Adyuvantes para vacunas contra el virus sincitico respiratorio.
US5652334A (en) * 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
EP0735893B1 (en) * 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JPH09508353A (ja) 1993-11-02 1997-08-26 アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ 分子多様性の合成及びスクリーニング
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
WO1995020666A2 (en) * 1994-01-27 1995-08-03 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5910427A (en) * 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6022859A (en) * 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) * 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EE9900461A (et) * 1997-04-15 2000-06-15 Farmaceutisk Laboratorium Ferring A/S Modifitseeritud TNFa molekulid, neid kodeeriv DNA ning selliseid TNFa molekule ja DNA sisaldavad vaktsiinid
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6432710B1 (en) * 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6727349B1 (en) * 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7629311B2 (en) * 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US7282570B2 (en) * 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2000077178A1 (en) * 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
HK1044564B (en) * 1999-09-03 2010-05-28 拉莫特大学应用研究和工业开发有限公司 Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
JP2001076325A (ja) * 1999-09-07 2001-03-23 Canon Inc 変位検出装置及び情報記録装置
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
SI1257584T2 (sl) * 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
WO2002003911A2 (en) * 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
AU2002251682A1 (en) * 2000-11-02 2002-08-28 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE10064895A1 (de) * 2000-12-23 2002-06-27 Alstom Switzerland Ltd Kühlsystem und Verfahren zur Kühlung eines Strömungsmaschinengehäuses
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2003265509A (ja) * 2002-03-18 2003-09-24 Masaharu Takenaga 脱腸帯
TWI221474B (en) * 2002-10-23 2004-10-01 Chung Shan Inst Of Science Method for preparing melamine salt of bis-(pentaerythritol phosphate) phosphoric acid
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005002444A1 (en) * 2003-07-07 2005-01-13 Agency For Science, Technology And Research Method and apparatus for extracting third ventricle information
CA2445743A1 (en) * 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
AR047062A1 (es) * 2003-12-17 2006-01-04 Wyeth Corp Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
AU2004299501B2 (en) * 2003-12-17 2010-12-23 Wyeth Llc Immunogenic peptide carrier conjugates and methods of producing same
US20050214222A1 (en) * 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
CA2830939C (en) * 2004-07-02 2017-02-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CN101027391A (zh) * 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
WO2006047670A2 (en) * 2004-10-26 2006-05-04 Wyeth Methods for assessing antibodies to neurodegenerative disease-associated antigens
US20060153772A1 (en) * 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20060240486A1 (en) * 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
TW200635607A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896504B1 (en) * 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR20080095836A (ko) * 2005-11-10 2008-10-29 로스캄프 리서치 엘엘씨 Ａ―베타 펩티드 단편에 의한 혈관형성의 조정
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MX384227B (es) * 2007-12-28 2025-03-14 Univ Tennessee Res Found Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.

Also Published As

Publication number Publication date
NO20053862L (no) 2005-10-31
MXPA05008156A (es) 2005-09-30
PL378571A1 (pl) 2006-05-02
ES2545765T3 (es) 2015-09-15
CR7922A (es) 2006-02-07
RU2005127429A (ru) 2006-02-10
WO2004069182A2 (en) 2004-08-19
ZA200505782B (en) 2006-09-27
KR20050118669A (ko) 2005-12-19
US20040213800A1 (en) 2004-10-28
HRP20050670A2 (en) 2005-12-31
NZ567324A (en) 2009-08-28
EP1594969A4 (en) 2006-07-26
CA2513722A1 (en) 2004-08-19
AU2004209981B2 (en) 2009-02-26
RU2390350C2 (ru) 2010-05-27
NO20053862D0 (no) 2005-08-18
EP1594969B1 (en) 2015-05-20
WO2004069182A3 (en) 2005-03-03
US20060188512A1 (en) 2006-08-24
US20080279873A1 (en) 2008-11-13
JP2006516639A (ja) 2006-07-06
UA87453C2 (ru) 2009-07-27
BRPI0407058A (pt) 2006-01-17
AU2004209981A1 (en) 2004-08-19
CN1745175A (zh) 2006-03-08
EP1594969A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
ECSP055939A (es) Inmunizacion activa para generar anticuerpos para beta-a soluble
ES2407429T3 (es) Vacuna terapéurica
ES2339447T3 (es) Procedimiento para prevenir y tratar la enfermedad de alzehimer (ad).
CN106390107B (zh) 病理tau蛋白的免疫靶向
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
RU2012101485A (ru) Биспецифические четырехвалентные антигенсвязывающие белки
CN102224168B (zh) 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物
AR058326A1 (es) Anticuerpo monoclonal
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
SG173214A1 (en) Immunological methods and compositions for the treatment of alzhemier's disease
WO2009086539A3 (en) Treatment and prophylaxis of amyloidosis
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
RU2017104642A (ru) Новое антитело против tie-2 человека
RU2014140116A (ru) Антитела против pdgf-c
JP2018530574A5 (OSRAM)
RU2010150754A (ru) АНТИТЕЛА ПРОТИВ PirB
RU2001130068A (ru) Антиидиотипические антитела к антителам, которые ингибируют связывание иммуноглобулина с его высокоаффинным рецептором
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
Park et al. A Novel Aβ B-cell epitope Vaccine, Aβ1-10 with carrier protein OVA and KLH reduce Aβ-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer’s disease
ES2747899T3 (es) Conjugado amiloide y usos y procedimientos del mismo
JPWO2020070225A5 (OSRAM)
RU2353389C2 (ru) Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций